

ALEXION PHARMACEUTICALS INC  
Form 8-K  
December 14, 2005

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(D) OF THE**  
**THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **December 9, 2005**

**ALEXION PHARMACEUTICALS, INC.**

---

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>000-27756</b>	<b>13-3648318</b>
<hr/>	<hr/>	<hr/>
(State or other jurisdiction of of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

**352 Knotter Drive, Cheshire, Connecticut 06410**

---

(Address of Principal Executive Offices) (Zip Code)

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

Registrant's telephone number, including area code: **(203) 272-2596**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year End.**

On December 9, 2005, the board of directors of Alexion Pharmaceuticals, Inc. (the Company ) pursuant to the Company s Amended and Restated Bylaws unanimously approved a change in the Company s fiscal year end from July 31 to December 31. The Company intends to file a transition report on Form 10-K covering the five months period from August 1, 2005 to December 31, 2005 within 60 days of December 31, 2005.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: December 14, 2005

By: /s/ THOMAS I. H. DUBIN  
**Name: Thomas I. H. Dubin**

**Title: Senior Vice President and General Counsel**